Loomis, Sayles & Company
AXDX

Loomis, Sayles & Company’s Accelerate Diagnostics AXDX Stock Holding History

Loomis, Sayles & Company’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-45,348
Closed -$10.4M – 879
2018
Q1 		$10.4M Sell
45,348
-17,811
-28% -$4.68M 0.02% 411
2017
Q4 		$16.5M Sell
63,159
-581
-0.9% -$136K 0.03% 320
2017
Q3 		$14.3M Sell
63,740
-1,926
-3% -$473K 0.03% 351
2017
Q2 		$18M Sell
65,666
-2,237
-3% -$606K 0.04% 286
2017
Q1 		$16.4M Buy
67,903
+13,677
+25% +$3.12M 0.04% 314
2016
Q4 		$11.3M Sell
54,226
-2,787
-5% -$662K 0.03% 409
2016
Q3 		$15.5M Buy
57,013
+49,374
+646% +$10.9M 0.04% 332
2016
Q2 		$1.1M Buy
+7,639
New +$1.02M ﹤0.01% 570

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Loomis, Sayles & Company's AXDX Position: Q2 2018 in Review

Loomis, Sayles & Company sold out of Accelerate Diagnostics (AXDX) in Q2 2018, closing a stake of 45,348 shares — an estimated $10.4M sold.

Loomis, Sayles & Company first reported a position in AXDX in Q2 2016 and held it in 8 quarters. The position peaked at $18M in Q2 2017. 116 funds tracked by Wall St. Rank hold AXDX as of Q2 2018.

  • Loomis, Sayles & Company reported no remaining Accelerate Diagnostics position as of Q2 2018 after selling out during the quarter.
  • Loomis, Sayles & Company sold 45,348 Accelerate Diagnostics shares in Q2 2018, an estimated $10.4M.
  • Loomis, Sayles & Company first reported a position in Accelerate Diagnostics in Q2 2016 and held it in 8 quarters.
  • Loomis, Sayles & Company's Accelerate Diagnostics position peaked at $18M in Q2 2017.
  • 116 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2018.

Based on Loomis, Sayles & Company's 13F filing for Q2 2018, filed 14 Aug 2018.